# Telormedix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/telormedix

- Industry: Pharmaceuticals
- Headquarters: Switzerland
- Website: www.telormedix.com
- Total disclosed funding: $32M
- Latest round: Series B (Dec 2, 2013)
- Investors on record: 5

## About

Telormedix SA is an innovative biotechnology company focused on developing targeted therapeutics and diagnostics for cancer treatment, aiming to improve patient outcomes through advanced medical solutions.Founded in 2007 in Switzerland, Telormedix SA specializes in biotechnology solutions, primarily targeting cancer therapies. The company has completed 8 deals to date and recently secured funding through a Series B round amounting to CHF 6.000 mn from investors including Aravis and ProQuest Investments. The headquarters is located in Switzerland, and there is no mention of subsidiaries or a parent company. The founder's history and previous ventures are not detailed in the available information.Telormedix SA develops targeted therapeutics and diagnostics aimed at enhancing cancer treatment efficacy. Their product portfolio includes innovative therapies designed to improve treatment precision and patient quality of life, catering to healthcare providers and researchers in the oncology field.While specific revenue figures are not provided, Telormedix SA operates under a business model that supports sustainable growth and investment in its product development pipeline. The company’s focus on targeted cancer therapies indicates a structured approach to revenue generation through strategic partnerships and collaborations within the medical research community.Telormedix SA's future growth strategy includes the development and launch of new cancer therapies designed to enter clinical trials in the upcoming years. The recent Series B funding will facilitate the acceleration of product development and expansion into new international markets, enhancing the company's global presence. Additionally, the exit of NextTech Invest indicates a strategic repositioning as the company seeks to attract new investment and partnerships to further its research initiatives.

## Funding rounds

- Series B, Dec 2, 2013, $6.8M — Aravis, ProQuest Investments
- Series B, Jan 10, 2012, $7.9M — Aravis, ProQuest Investments
- Series A, Sep 30, 2008, $18M — Aravis, ProQuest Investments, BSI Group, Nextech, Generali Group

## Investors

- Aravis (https://capitalatlas.ai/funds/aravis) — Series A, Series B
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series A, Series B
- BSI Group — Series A
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A
- Generali Group — Series A